Literature DB >> 33222258

Bystanders, risks, and consent.

Helen Frowe1.   

Abstract

This paper considers the moral status of bystanders affected by medical research trials. Recent proposals advocate a very low threshold of permissible risk imposition upon bystanders that is insensitive to the prospective benefits of the trial, in part because we typically lack bystanders' consent. I argue that the correct threshold of permissible risk will be sensitive to the prospective gains of the trial. I further argue that one does not always need a person's consent to expose her to significant risks of even serious harm for the sake of others. That we typically need the consent of participants is explained by the fact that trials risk harmfully using participants, which is very hard to justify without consent. Bystanders, in contrast, are harmed as a side-effect, which is easier to justify. I then consider whether the degree of risk that a trial may impose on a bystander is sensitive to whether she is a prospective beneficiary of that trial.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  bystanders; human subjects research; informed consent; research ethics; research subjects; risk

Year:  2019        PMID: 33222258      PMCID: PMC7684685          DOI: 10.1111/bioe.12673

Source DB:  PubMed          Journal:  Bioethics        ISSN: 0269-9702            Impact factor:   1.898


  7 in total

1.  What makes clinical research ethical?

Authors:  E J Emanuel; D Wendler; C Grady
Journal:  JAMA       Date:  2000 May 24-31       Impact factor: 56.272

2.  Medical research, risk, and bystanders.

Authors:  Jonathan Kimmelman
Journal:  IRB       Date:  2005 Jul-Aug

3.  What is a "minor" increase over minimal risk?

Authors:  David Wendler; Ezekiel J Emanuel
Journal:  J Pediatr       Date:  2005-11       Impact factor: 4.406

4.  Protecting third parties in human subjects research.

Authors:  David B Resnik; Richard R Sharp
Journal:  IRB       Date:  2006 Jul-Aug

5.  Missing the forest: further thoughts on the ethics of bystander risk in medical research.

Authors:  Jonathan Kimmelman
Journal:  Camb Q Healthc Ethics       Date:  2007       Impact factor: 1.284

6.  Third-party risks in research: should IRBs address them?

Authors:  Daniel M Hausman
Journal:  IRB       Date:  2007 May-Jun

7.  What can the lived experience of participating in risky HIV cure-related studies establish?

Authors:  Nir Eyal
Journal:  J Med Ethics       Date:  2018-01-10       Impact factor: 2.903

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.